![]() Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. | Hetero Hetero is a generic pharmaceutical company engaged in the development, manufacturing, and marketing of chemical and biologic drugs. | ||
Founding Date | Founding Date 1863 | Founding Date 1982 | Founding Date 1993 |
Type | Type Public | Type Subsidiary | Type Private |
Tags | |||
Locations | Locations Morris Plains, US HQ | Locations Hyderabad, IN HQ Norwest, AU Sao Paulo, BR Beijing, CN Nanjing Shi, CN Nanjing Shi, CN Bogotá, CO see more | |
Employees | Employees 92,8152% decrease | Employees 104 | Employees 6,8372% increase |
Financial | |||
Revenue (est.) | Revenue (est.) €46.6b (FY, 2024) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) N/A |
Cost of goods | Cost of goods €12b (FY, 2024) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit €35.8b (FY, 2024) | Gross profit $295k (FY, 2019) | Gross profit N/A |
Net income | Net income (€2.5b) (FY, 2024) | Net income ($357.3m) (FY, 2019) | Net income N/A |
Operating ⚠ | |||
Countries | Countries 83 (FY, 2021) | Countries N/A | Countries 126 (Jan, 2021) |
Patent Applications (US) | Patent Applications (US) N/A | Patent Applications (US) 230 (Sep, 2022) | Patent Applications (US) 23 (Jan, 2021) |
Patents (US) | Patents (US) N/A | Patents (US) 405 (Sep, 2022) | Patents (US) 38 (Jan, 2021) |
Funding | |||
Total funding raised | Total funding raised $ 3.5b | Total funding raised $ 30m | Total funding raised N/A |
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companyHetero is a generic pharmaceutical company engaged in the development, manufacturing, and marketing of chemical and biologic drugs.
View company